A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-cell Lymphoma Recurrent · Diffuse Large B Cell Lymphoma Refractory

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact: Study coordinator (Haiyan Yang, PhD) · yanghy@zjcc.org.cn · 0086-571-88122192
Contact: Study coordinator (Xi Chen, MD) · zjuchenxi@126.com · 0086-571-88122192
Xi Chen, MD (Sub-investigator)

Study leads

Haiyan Yang
Principal Investigator
Zhejiang Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Registry of Older Patients With Cancer

Chronic Myeloproliferative Disorders · Cognitive/Functional Effects · Leukemia

Abroad (travel likely)Recruiting

Boone, United States · Chapel Hill, United States

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Hodgkin Disease · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30+ Anaplastic Large Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Brain and Central Nervous System Tumors · Chronic Myeloproliferative Disorders · Leukemia

Abroad (travel likely)Recruiting

Detroit, United States

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Relapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Irvine, United States · Los Angeles, United States